Methods for measuring tau pathology in transgenic mouse models

Stefanie K. Forest, Christopher M. Acker, Cristina D'abramo, Peter Davies

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In Alzheimer's disease (AD) and tauopathies, tau becomes hyperphosphorylated, undergoes a conformational change, and becomes aggregated and insoluble. There are three methods commonly used to study the insoluble tau fraction, two that utilize detergents (Sarkosyl and RIPA) and another that does not (insoluble). However, these methods require large amounts of homogenate for a relatively low yield of the insoluble fraction, which can be problematic when dealing with small tissue samples. Furthermore, the most common way of analyzing this material is through densitometry of immunoblots, offering only semiquantitative measurements. We provide a comparison of the three methods commonly used (Sarksoyl, RIPA, and insoluble) through immunoblot and ELISA analyses. Finally, we tested a new method to determine aggregated tau levels, utilizing a monoantibody tau ELISA. The insoluble fractions of four different mouse models (P301 L, htau, wild type, and knockout) as well as human AD and control brains were examined. There were significant correlations between the three insoluble methods for both total tau and pS396/404 tau measured by immunoblot or ELISA analyses. Additionally, the results from the ELISA method correlated significantly with those from immunoblot analyses. Finally, the monoantibody assay on the lysate significantly correlated with the total tau ELISAs performed on the three insoluble preparations. Taken together, these results suggest that all three insoluble preparation methods offer similar results for measuring insoluble tau in either mouse or human brains. In addition the new monoantibody ELISA offers a simple quantitative method to measure the amount of aggregated tau in both human and mouse brains.

Original languageEnglish (US)
Pages (from-to)463-471
Number of pages9
JournalJournal of Alzheimer's Disease
Volume33
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Transgenic Mice
Pathology
Enzyme-Linked Immunosorbent Assay
Alzheimer Disease
Brain
Tauopathies
Densitometry
Detergents

Keywords

  • Alzheimer's disease
  • ELISA
  • immunoblotting
  • methodology
  • tau protein
  • transgenic mice

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Methods for measuring tau pathology in transgenic mouse models. / Forest, Stefanie K.; Acker, Christopher M.; D'abramo, Cristina; Davies, Peter.

In: Journal of Alzheimer's Disease, Vol. 33, No. 2, 01.01.2013, p. 463-471.

Research output: Contribution to journalArticle

Forest, Stefanie K. ; Acker, Christopher M. ; D'abramo, Cristina ; Davies, Peter. / Methods for measuring tau pathology in transgenic mouse models. In: Journal of Alzheimer's Disease. 2013 ; Vol. 33, No. 2. pp. 463-471.
@article{52cb9bb12e40495ea41d0874b9700431,
title = "Methods for measuring tau pathology in transgenic mouse models",
abstract = "In Alzheimer's disease (AD) and tauopathies, tau becomes hyperphosphorylated, undergoes a conformational change, and becomes aggregated and insoluble. There are three methods commonly used to study the insoluble tau fraction, two that utilize detergents (Sarkosyl and RIPA) and another that does not (insoluble). However, these methods require large amounts of homogenate for a relatively low yield of the insoluble fraction, which can be problematic when dealing with small tissue samples. Furthermore, the most common way of analyzing this material is through densitometry of immunoblots, offering only semiquantitative measurements. We provide a comparison of the three methods commonly used (Sarksoyl, RIPA, and insoluble) through immunoblot and ELISA analyses. Finally, we tested a new method to determine aggregated tau levels, utilizing a monoantibody tau ELISA. The insoluble fractions of four different mouse models (P301 L, htau, wild type, and knockout) as well as human AD and control brains were examined. There were significant correlations between the three insoluble methods for both total tau and pS396/404 tau measured by immunoblot or ELISA analyses. Additionally, the results from the ELISA method correlated significantly with those from immunoblot analyses. Finally, the monoantibody assay on the lysate significantly correlated with the total tau ELISAs performed on the three insoluble preparations. Taken together, these results suggest that all three insoluble preparation methods offer similar results for measuring insoluble tau in either mouse or human brains. In addition the new monoantibody ELISA offers a simple quantitative method to measure the amount of aggregated tau in both human and mouse brains.",
keywords = "Alzheimer's disease, ELISA, immunoblotting, methodology, tau protein, transgenic mice",
author = "Forest, {Stefanie K.} and Acker, {Christopher M.} and Cristina D'abramo and Peter Davies",
year = "2013",
month = "1",
day = "1",
doi = "10.3233/JAD-2012-121354",
language = "English (US)",
volume = "33",
pages = "463--471",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Methods for measuring tau pathology in transgenic mouse models

AU - Forest, Stefanie K.

AU - Acker, Christopher M.

AU - D'abramo, Cristina

AU - Davies, Peter

PY - 2013/1/1

Y1 - 2013/1/1

N2 - In Alzheimer's disease (AD) and tauopathies, tau becomes hyperphosphorylated, undergoes a conformational change, and becomes aggregated and insoluble. There are three methods commonly used to study the insoluble tau fraction, two that utilize detergents (Sarkosyl and RIPA) and another that does not (insoluble). However, these methods require large amounts of homogenate for a relatively low yield of the insoluble fraction, which can be problematic when dealing with small tissue samples. Furthermore, the most common way of analyzing this material is through densitometry of immunoblots, offering only semiquantitative measurements. We provide a comparison of the three methods commonly used (Sarksoyl, RIPA, and insoluble) through immunoblot and ELISA analyses. Finally, we tested a new method to determine aggregated tau levels, utilizing a monoantibody tau ELISA. The insoluble fractions of four different mouse models (P301 L, htau, wild type, and knockout) as well as human AD and control brains were examined. There were significant correlations between the three insoluble methods for both total tau and pS396/404 tau measured by immunoblot or ELISA analyses. Additionally, the results from the ELISA method correlated significantly with those from immunoblot analyses. Finally, the monoantibody assay on the lysate significantly correlated with the total tau ELISAs performed on the three insoluble preparations. Taken together, these results suggest that all three insoluble preparation methods offer similar results for measuring insoluble tau in either mouse or human brains. In addition the new monoantibody ELISA offers a simple quantitative method to measure the amount of aggregated tau in both human and mouse brains.

AB - In Alzheimer's disease (AD) and tauopathies, tau becomes hyperphosphorylated, undergoes a conformational change, and becomes aggregated and insoluble. There are three methods commonly used to study the insoluble tau fraction, two that utilize detergents (Sarkosyl and RIPA) and another that does not (insoluble). However, these methods require large amounts of homogenate for a relatively low yield of the insoluble fraction, which can be problematic when dealing with small tissue samples. Furthermore, the most common way of analyzing this material is through densitometry of immunoblots, offering only semiquantitative measurements. We provide a comparison of the three methods commonly used (Sarksoyl, RIPA, and insoluble) through immunoblot and ELISA analyses. Finally, we tested a new method to determine aggregated tau levels, utilizing a monoantibody tau ELISA. The insoluble fractions of four different mouse models (P301 L, htau, wild type, and knockout) as well as human AD and control brains were examined. There were significant correlations between the three insoluble methods for both total tau and pS396/404 tau measured by immunoblot or ELISA analyses. Additionally, the results from the ELISA method correlated significantly with those from immunoblot analyses. Finally, the monoantibody assay on the lysate significantly correlated with the total tau ELISAs performed on the three insoluble preparations. Taken together, these results suggest that all three insoluble preparation methods offer similar results for measuring insoluble tau in either mouse or human brains. In addition the new monoantibody ELISA offers a simple quantitative method to measure the amount of aggregated tau in both human and mouse brains.

KW - Alzheimer's disease

KW - ELISA

KW - immunoblotting

KW - methodology

KW - tau protein

KW - transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=84872451137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872451137&partnerID=8YFLogxK

U2 - 10.3233/JAD-2012-121354

DO - 10.3233/JAD-2012-121354

M3 - Article

C2 - 22976073

AN - SCOPUS:84872451137

VL - 33

SP - 463

EP - 471

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -